• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Glenmark Pharmaceuticals is clawing back to favour in the bourses as analysts reconsider the potential of domestic markets for pharmaceutical companies. Market experts say that some brokerages are advising a buy at this counter every time the price drops. Glenmark is seen as a value buy in this sector, say experts.

The stock has been steadily gaining the past month. Volumes have been healthy in the counter. The stock closed at Rs 314.90 on Friday, after touching an intra-day high of Rs 324.

Veena Venugopal

More Stories on : Stock Markets | Ear to the ground | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Vimta Labs makes pref allotments

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line